PT - JOURNAL ARTICLE AU - Dawson, Kristin AU - Carangan, Athena May Jean M. AU - Klunder, Jessica AU - Carreras-Gallo, Natalia AU - Sehgal, Raghav AU - Megilligan, Samantha AU - Askins, Benjamin C. AU - Perkins, Nicole AU - Mendez, Tavis L. AU - Smith, Ryan AU - Dawson, Matthew AU - Mallin, Michael AU - Higgins-Chen, Albert T. AU - Dwaraka, Varun B. TI - Ketamine treatment effects on DNA methylation and Epigenetic Biomarkers of aging AID - 10.1101/2024.09.10.24313258 DP - 2024 Jan 01 TA - medRxiv PG - 2024.09.10.24313258 4099 - http://medrxiv.org/content/early/2024/09/11/2024.09.10.24313258.short 4100 - http://medrxiv.org/content/early/2024/09/11/2024.09.10.24313258.full AB - Major depressive disorder (MDD) and posttraumatic stress disorder (PTSD) are debilitating psychiatric conditions associated with poor health outcomes similarly observed in non-pathological aging. Ketamine is a dissociative anesthetic and NMDA receptor antagonist with demonstrated rapid reduction in symptoms associated with Treatment Resistant Depression (TRD) and PTSD. Ketamine’s effects on biological aging have not been extensively studied among patients with moderate to severe symptoms of depression and/or trauma. To address this gap, this study looked at the changes in non-epigenetic measures, DNA methylation levels, immune cell composition, and biological age based on various epigenetic biomarkers of aging, of 20 participants at baseline and after completion of a 2-3 week treatment course of 0.5 mg/kg ketamine infusions in individuals with MDD or PTSD. As expected, depression and PTSD scores decreased in participants following ketamine infusion treatments as measured by the PHQ-9 and PCL-5. We observed a reduction in epigenetic age in the OMICmAge, GrimAge V2, and PhenoAge biomarkers. In order to better understand the changes in epigenetic age, we also looked at the underlying levels of various Epigenetic Biomarker Proxies (EBPs) and surrogate protein markers and found significant changes following ketamine treatment. The results are consistent with existing literature on ketamine’s effects on different biomarkers. These results underline the ability of GrimAge V2, PhenoAge, and OMICmAge in particular, to capture signals associated with key clinical biomarkers, and add to the growing body of literature on ketamine’s epigenetic mechanisms and their effect on biological aging.Competing Interest StatementKD, JS, and SM are employed with Expedition Mental Health. AC, NCG, TLM, RS, MD, MM, and VBD are employed with TruDiagnostic Inc. BCA is employed with Wild Health. ATH and RS have received consulting fees from TruDiagnostic Inc. for work unrelated to the present manuscript, and are named as inventors on a patent for the SystemsAge scores that are licensed to TruDiagnostic Inc.Clinical TrialNCT05294835Funding StatementDr. Higgins-Chen was supported by a Pilot Grant from the Claude D. Pepper Older Americans Independence Center at Yale School of Medicine (P30AG021342) as well as grants from the NIH (NIA R01AG065403).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of INSTITUTE OF REGENERATIVE AND CELLULAR MEDICINE gave ethical approval for this work. Approval number: IRCM-2022-320I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the corresponding author.